Xeris Biopharma Holdings (LTS:0A8E) Gross-Profit-to-Asset % : 49.84% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Xeris Biopharma Holdings Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Xeris Biopharma Holdings's annualized Gross Profit for the quarter that ended in Sep. 2024 was $162.7 Mil. Xeris Biopharma Holdings's average Total Assets over the quarter that ended in Sep. 2024 was $326.4 Mil. Therefore, Xeris Biopharma Holdings's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 was 49.84%.

Xeris Biopharma Holdings Gross-Profit-to-Asset % Historical Data

The historical data trend for Xeris Biopharma Holdings's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings Gross-Profit-to-Asset % Chart

Xeris Biopharma Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

0.98

8.28

15.65

27.00

40.55

Xeris Biopharma Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															48.88	45.29	42.07	48.21	49.84

Competitive Comparison of Xeris Biopharma Holdings's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Xeris Biopharma Holdings's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xeris Biopharma Holdings's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xeris Biopharma Holdings's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Xeris Biopharma Holdings's Gross-Profit-to-Asset % falls into.

Xeris Biopharma Holdings Gross-Profit-to-Asset % Calculation

Xeris Biopharma Holdings's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	135.269	/	( (344.522	+	322.602)	/ 2 )
	=	135.269	/	333.562
	=	40.55 %

Xeris Biopharma Holdings's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	162.7	/	( (331.733	+	321.104)	/ 2 )
	=	162.7	/	326.4185
	=	49.84 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Xeris Biopharma Holdings Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Xeris Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (LTS:0A8E) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

XERS:USA 2B30:Germany

Address

1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607

Website

https://www.xerispharma.com

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Xeris Biopharma Holdings Headlines

No Headlines